SA
SCYX logo
SCYNEXIS, Inc.(SCYX)
Closing price · checked 8:38 PM ETAbout this dataData status
$2.38▼-0.23 (-8.64%)
Extended:$2.38+0.00 (+0.00%)· 8:38 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

SCYNEXIS, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for difficult-to-treat infections, particularly in the area of antifungal treatments. Its lead product candidate, SCY-078, targets invasive fungal infections and has shown promising results in clinical trials, positioning the company to address significant unmet medical needs in the healthcare sector.

HealthcarePharmaceuticalslow - The company has high fixed costs associated with R&D and clinical trials, with minimal revenue generation until product approval.

Business Overview

01Product sales from SCY-078 (0% of total, as it is still in clinical stages)
02Potential licensing agreements (0% of total, contingent on successful trials)
03Grants and research funding (0% of total, primarily for R&D)

SCYNEXIS primarily focuses on developing antifungal therapies, with SCY-078 being its flagship product. The company aims to monetize its innovations through product sales post-approval, licensing agreements, and grants for research. Its competitive advantage lies in its proprietary technology and a strong pipeline addressing high unmet needs in antifungal treatments, which are often resistant to existing therapies.

What Moves the Stock

Clinical trial results for SCY-078, particularly Phase 3 outcomes

Regulatory approvals from the FDA or EMA

Partnership announcements or licensing deals with larger pharmaceutical companies

Market adoption rates post-launch

Watch on Earnings
Clinical trial milestonesCash burn ratePartnership revenue potential

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption in antifungal treatment methodologies

Emergence of alternative therapies from larger pharmaceutical companies

Generic competition post-patent expiration

High cash burn rate leading to potential liquidity issues

Dependence on external funding for R&D

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - The demand for antifungal treatments is relatively inelastic, as these are essential medications regardless of economic conditions.

Interest Rates

Moderate - Rising interest rates could increase the cost of capital for R&D funding, impacting the company's ability to finance its clinical trials.

Credit

minimal - The company's low debt levels (Debt/Equity of 0.05) reduce credit risk.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in biotech.

high - The stock is likely to exhibit high volatility due to binary outcomes from clinical trials.

Key Metrics to Watch
Clinical trial enrollment rates
FDA approval timelines for SCY-078
Cash runway (current cash reserves vs. burn rate)
Market size for antifungal treatments
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.